Thursday, May 1, 2014
By Dr. James W. Stark
A study presented at the AAN examined the use of estriol in combination with copaxone in the treatment of 158 relapsing-remitting MS patients. At 12 months, the group treated with both copaxone and estriol had improved relapse rates, however that effect was less apparent at 24 months. The relationship between estrogen and MS is an important area of active study, although the IMSMP does not recommend supplementation for most patients
Tisch MS Research Center of New York
521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900
Look for the IFF Building on the North side of 57th Street across from the CBS building
Support Tisch MS
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.